U.S. markets closed
  • S&P Futures

    3,607.00
    +5.50 (+0.15%)
     
  • Dow Futures

    28,883.00
    +82.00 (+0.28%)
     
  • Nasdaq Futures

    11,022.50
    -13.00 (-0.12%)
     
  • Russell 2000 Futures

    1,674.20
    +4.40 (+0.26%)
     
  • Crude Oil

    81.77
    +2.28 (+2.87%)
     
  • Gold

    1,672.30
    +0.30 (+0.02%)
     
  • Silver

    19.12
    +0.08 (+0.43%)
     
  • EUR/USD

    0.9808
    -0.0012 (-0.12%)
     
  • 10-Yr Bond

    3.8040
    +0.0570 (+1.52%)
     
  • Vix

    31.62
    -0.22 (-0.69%)
     
  • GBP/USD

    1.1173
    +0.0050 (+0.45%)
     
  • USD/JPY

    144.6930
    +0.2500 (+0.17%)
     
  • BTC-USD

    19,209.28
    -102.90 (-0.53%)
     
  • CMC Crypto 200

    443.49
    +0.06 (+0.01%)
     
  • FTSE 100

    6,893.81
    +12.22 (+0.18%)
     
  • Nikkei 225

    25,937.21
    -484.89 (-1.84%)
     

AVEO Oncology Announces Participation at the H.C. Wainwright Global Investment Conference

·2 min read
AVEO Pharmaceuticals, Inc.
AVEO Pharmaceuticals, Inc.

BOSTON, May 18, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will participate in a fireside chat at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022 at 1:30 p.m. eastern time.

A live webcast of the fireside chat can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast will be archived for 30 days following the presentation date.

About AVEO Pharmaceuticals, Inc.

AVEO is a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO continues to develop FOTIVDA in immuno-oncology and other novel targeted combinations in RCC and other indications, and has other investigational programs in clinical development. AVEO is committed to creating an environment of diversity, equity and inclusion to diversify representation within the company.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements of AVEO within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Actual results or events could differ materially due to a number of important factors, including risks discussed in the sections titled “Risk Factor Summary,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources” included in AVEO’s most recent Annual Report on Form 10-K, its quarterly reports on Form 10-Q and in other filings that AVEO makes with the SEC. The forward-looking statements in this press release represent AVEO’s views as of the date of this press release. AVEO anticipates that subsequent events and developments may cause its views to change. While AVEO may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing AVEO’s views as of any date other than the date of this press release.

AVEO Invest Relations Contact:
Hans Vitzthum
LifeSci Advisors, LLC
Hans@LifeSciAdvisors.com
(617) 430-7578

AVEO Public Relations Contact:
John F. Kouten
JFK Communications, Inc.
(609) 241-7352
jfkouten@jfkhealth.com

Source: AVEO Oncology